Post–CAR T relapse in MCL is associated with median PFS ~2.5 months and OS ~5.4 months, underscoring a high-need salvage setting without an established standard. Relapse biopsy demonstrated retained ...
Phase 2 data show promising antiviral activity with tobevibart plus elebsiran in hepatitis D, supporting further evaluation in the phase 3 ECLIPSE program. First identified in the late 1970s by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results